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Abstract
Many countries have national guidelines for the prevention and control of methicillin-resistant Staphylococcus aureus (MRSA) that are
similar in approach. The evidence base for many recommendations is variable, and often, in the drafting of such guidelines, the evidence
is either not analysed or not speciﬁcally reviewed. Guidelines usually recommend screening and early detection, hand hygiene, patient
isolation or cohorting, and decolonization. Although many components of a prevention and control programme appear to be self-evi-
dent, e.g. patient isolation, the scientiﬁc base underpinning these is poor, and scientiﬁcally rigorous studies are required. Nonetheless,
where measures, based on what evidence there is and on common sense, are implemented, and where the necessary resources are
provided, MRSA can be controlled. In The Netherlands and in other low-prevalence countries, these measures have largely kept health-
care facilities MRSA-free. In MRSA-endemic countries, such as Spain and Ireland, national guidelines are often not fully implemented,
owing to apparently inadequate resources or a lack of will. However, recent studies from France and Australia demonstrate what is
possible in high-prevalence countries when best practice is effectively implemented, with potentially major beneﬁts for patients, the
respective health services, and society.
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Background
Methicillin-resistant Staphylococcus aureus (MRSA) is a well-
recognized cause of healthcare-associated infection (HCAI),
and is now increasingly seen outside acute healthcare facili-
ties in some countries. Its clinical impact, in terms of morbid-
ity and mortality, is well recognized. In an observational
study of 198 intensive-care units (ICUs) in 24 European
countries, S. aureus was the most common pathogen impli-
cated in sepsis, and 14% of isolates were MRSA [1]. MRSA
bloodstream infection is associated with signiﬁcant mortality.
In a meta-analysis of studies of bloodstream infection due to
MRSA and methicillin-susceptible S. aureus, there was a signif-
icant association between death and MRSA [2].
Given the prevalence of MRSA in many European coun-
tries, its clinical impact, and the concern of patients, the pub-
lic and many healthcare workers, there is widespread
recognition of the need for a multidisciplinary approach to
prevention and control. However, the prevalence of MRSA
varies considerably among European countries, and from a
review of national guidelines, there are some variations in
the strategies adopted and in the effectiveness of their
implementation.
Guidelines and Recommendations
Although many institutions and professional groups have
attempted to address the spread and control of MRSA, the
implementation of evidence-based guidelines has been some-
what ad hoc. For example, the European Practice Database
has collected data on renal practice in different European
countries, and found that 1.3% of haemodialysis patients are
MRSA-positive [3]. However, in Greece, Italy, England and
Belgium, over 50% of centres screen for MRSA, as compared
with <10% of centres in Slovakia, Norway, the Czech Repub-
lic and Scotland [3].
Guidelines from Germany, New Zealand, North America,
The Netherlands, Ireland and the UK have recently been
reviewed [4]. Although many of these guidelines share com-
mon themes, e.g. the importance of early identiﬁcation of
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MRSA, patient isolation or cohorting, and hand hygiene, the
processes by which these guidelines were developed vary
somewhat in terms of the analysis of the evidence base. In
addition, given the apparent similarity of many aspects of the
approach among the various countries, it is somewhat
surprising that there is such a range of prevalence among
countries, e.g. The Netherlands (low prevalence) and Spain
and Ireland (high prevalence). When the literature on inter-
ventions to control and prevent MRSA is reviewed, there is
often an absence of detail about the infrastructure in which
outbreaks or studies occur, and the degree to which there is
full support from local organizational and national agencies
[5]. A recent assessment of antimicrobial drug use and infec-
tion control practices in European hospitals conﬁrms this, as
it showed that there were higher levels of MRSA where
there were problems in implementing isolation policies, and
that lower rates of MRSA were associated with the use of
alcohol-based hand hygiene [6].
The Evidence Base for MRSA Guidelines
Much of what is included in local or national recommenda-
tions for the prevention and control of MRSA is both logical
and self-evident, and the effectiveness of these interventions,
when implemented, can be seen in those countries where
the prevalence of MRSA infection is low, such as The Neth-
erlands. Nonetheless, it is often difﬁcult to determine from
the literature the degree to which individual speciﬁc compo-
nents of a strategy are effective, and where the emphasis is
best placed.
In a systematic review of the published literature between
1996 and 2004, well-conducted evaluations reporting the
economic beneﬁts arising from infection prevention and con-
trol interventions on MRSA were lacking, and for four of ﬁve
speciﬁc interventions, i.e. screening patients before or on
admission, the use of surveillance data, isolation/cohorting,
and decolonization, the conclusions were at best tentative
and far from conclusive, not withstanding the logic associated
with each of them [7].
Patient isolation is considered to be one of the most
important interventions in reducing the transmissibility of
healthcare associated infection. However, a recent review of
46 studies indicated that there were major methodological
weaknesses and inadequate reporting in much of the pub-
lished research [8]. There is a need for greater rigour in the
quality of publications that deal with the control and preven-
tion of HCAI. Recently, a set of standards or guidelines has
been published to enable researchers and others in the ﬁeld
to check the validity of their studies and results against a
check-list [9]. This approach should promote better studies
and enable us to have more valid scientiﬁc evidence for
much of what is currently practised and implemented in the
control and prevention of MRSA.
Current Practice
Although national and local guidelines are often disseminated,
it is essential to ascertain whether guidelines are partially or
fully implemented when trying to understand prevalence
data. In a survey of 36 UK adult cardiac surgical units during
2001, it was found that only 65% of units screened all
patients for MRSA, and 45% regularly screened long-term
patients remaining in the unit [10], even though the national
guidelines at the time identiﬁed cardiothoracic units as being
high-risk areas for MRSA and recommended admission
screening [11]. The authors concluded that there was wide
variation in practice within the UK for cardiac surgical units,
but that there needed to be some rationalization of preoper-
ative screening and the use of prophylactic antibiotics [10].
In Ireland, a follow-up review of the implementation of
recent national guidelines found that 43 of 49 acute hospitals
experienced barriers to their full implementation, and in four
hospitals there was no education programme on hand
hygiene [12].
A multidisciplinary approach that included education,
improved ward and theatre hygiene, preadmission, admis-
sion and weekly MRSA screening, isolation, and decoloniza-
tion, largely based on national guidelines [11], resulted in a
signiﬁcant decrease in both the unit acquisition of MRSA
and bloodstream MRSA infections, in a London cardiotho-
racic unit [13]. Also, in a survey of 207 general ICUs in the
UK, there was marked variation in practice, including the
ﬁndings that 75% of units screened patients on admission,
isolation cubicles were not present in 10% of units, and
24% of units did not routinely isolate patients with MRSA
[14]. These results suggest that up to now, in the UK,
national guidelines could not be or were not being imple-
mented. Although a recent UK study has suggested that
isolation in the ICU may not be as effective as originally
thought [15], there were confounding variables in that
study that would have offset the effectiveness of isolation,
e.g. suboptimal hand hygiene and admission screening for
MRSA, many of which were discussed in the accompanying
editorial [16].
In The Netherlands, there is an impressively low preva-
lence of MRSA in hospitals. In a Dutch study that assessed
the prevalence of MRSA among patients without risk
factors for MRSA carriage at the time of admission to
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hospital, only three MRSA carriers were identiﬁed, repre-
senting 0.3% of the survey population [17]. When out-
breaks of MRSA do occur in The Netherlands, it is clear
that considerable efforts are made, with the accompanying
resources, to ensure not only that any initial MRSA spread
is controlled, but also that MRSA is eradicated, illustrating
the effectiveness of the ‘search and destroy’ approach in
low-prevalence countries.
During a recent outbreak in a 700-bed Dutch hospital,
additional laboratory resources were provided, the aggres-
sive screening of patient and staff contacts was undertaken,
and additional infection prevention and control staff were
made available, to assist in outbreak management [18].
Therefore, although this represented an epidemic in a coun-
try with low MRSA prevalence rates, as compared with
endemic MRSA in many other European countries, best prac-
tice consistent with national guidelines (http://www.wip.nl/
UK/free_content/Richtlijnen/MRSA(1).pdf) was implemented
and the necessary resources, including ﬁnance, space and
personnel, were provided. This consistent and comprehen-
sive approach ensured that the outbreak was brought to an
end.
Although there are considerable costs associated with
such aggressive measures, they appear to be cost-effective.
Over a 10-year period (1991–2000), the aggressive imple-
mentation of MRSA control measures in The Netherlands
resulted in 2265 lost hospitalization days, but this ‘search
and destroy’ approach resulted in the probable prevention of
520 000 infections per year, and the cost of the policy was
€280 000 per year [19].
France has had a relatively high national prevalence of
MRSA, but efforts have been underway nationally and locally
in recent years to improve this situation, with encouraging
results. In a programme that involved three ICUs over
7 years, and that consisted in screening and contact precau-
tions, but not routine MRSA decolonization, there was a
reduction in MRSA acquired in the ICU from 7% to 2.8%
[20]. Similarly, in Australia, a series of interventions in a 35-
bed ICU resulted in a decline in the number of MRSA cases
in the ICU as well as throughout the hospital [21]. Finally, in
the USA, screening policies for MRSA vary among ICUs.
However, two recent surveys have highlighted the impor-
tance of routine ICU surveillance in establishing the true
prevalence of MRSA (both colonization and infection), and
the fact that this is an important component in reducing
MRSA rates, including MRSA bloodstream infection [22,23].
Therefore, the implementation of recommended measures,
whether they be enhanced screening for MRSA, improved
hand hygiene, or isolation/cohorting, is effective in reducing
rates or minimizing transmission.
Recent and Future Developments
The ﬁnding that, in general, national guidelines are not dis-
similar in terms of their strategic approach to the prevention
and control of MRSA suggests that the differences among
countries relates partly to the resources provided for HCAI
prevention and control, as well as the priority that is given
to such measures, i.e. the culture of the healthcare environ-
ment. Although there are some indications that in previously
high-prevalence European countries, such as France and
Slovenia, improvements have been made (http://www.rivm.
nl/earss/Images/EARSS%202006%20Def_tcm61-44176.pdf),
there is often discussion in low-prevalence countries of the
need to continue to implement aggressive control measures,
as these are perceived as being quite costly. A recent review
of current policy in The Netherlands in 2006, which was
requested by the Dutch Department of Health, concluded
that the current, aggressive ‘search and destroy’ approach
should be continued because it results in signiﬁcantly fewer
infections and reduced antibiotic costs (http://www.gr.nl/pdf.
php?ID=1461&p=1).
Guidelines need to be tailored to the speciﬁc clinical cir-
cumstances, without compromising the essential principles
underpinning them, but there needs to be acceptance from
the relevant healthcare professionals. In Canada, a working
group has provided clear and sensible advice for the speciﬁc
management of outbreaks of MRSA in neonatal ICUs [24].
This needs to be accompanied by greater consistency in
approach, as suggested by another recent Canadian survey.
Although 96% of hospitals screened for MRSA, only 21%
conducted regular prevalence surveys, 82% undertook decol-
onization, and 75% had restrictive antibiotic prescribing [25].
In addition, many countries have recognized the need for
guidelines on MRSA in the community to reﬂect the emer-
gence of true community-acquired strains and the phenome-
non of MRSA in healthcare facilities, such as acute hospitals,
‘spilling over’ into community units and primary care [26].
In the future there may be greater consistency in policies
both among institutions and among countries, with greater
commitment to their implementation on the part of national
and other bodies, driven by patient expectations and
demands. However, this will require appropriate governance
structures to ensure that a multidisciplinary approach can be
implemented. All healthcare workers must realize that the
prevention and control of HCAI is everyone’s responsibility.
However, this must be accompanied by suitable educational
programmes. Brady et al. found that over two-thirds of
surgical trainees in the UK were unaware of policies for the
transfer of MRSA-positive patients, and 62% were
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misinformed about the prevalence of MRSA bloodstream
infections [27]. This implies that, apart from an educational
deﬁcit, there may remain a perception that the prevention
and control of infection is largely the responsibility of special-
ist personnel, whose responsibility it is to minimize all infec-
tions, including those caused by MRSA.
The successful implementation of healthcare bundles to
reduce central line-associated infections [28] suggests that it
is possible to reduce HCAIs, including MRSA infections, to
an irreducible minimum, but this requires a major change in
attitude. However, such a change will result in improvements
in the quality and safety of patient care, and is likely to have
signiﬁcant cost beneﬁts for the health services and society. In
conclusion, guidelines for the prevention and control of
MRSA are effective if they are implemented and if they are
resourced. In many European countries, this requires a major
change in culture, so that the quality and safety of patient
care are prioritized.
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